Catheter Precision Announces Brief 10-Q Filing Delay
Catheter Precision (VTAK) has announced a brief delay in its Form 10-Q filing for Q1 2026, which is attributed to the complex accounting required for its recent acquisition of Fly Flyte, Inc. and Ponderosa Air, LLC. The company expects to file within the SEC's five-day extension and does not anticipate any significant changes to its quarterly results. Spark, TipRanks' AI Analyst, rates VTAK as Neutral due to weak financial performance and bearish technical trends, despite supportive corporate financing actions.
MAY 1·Stock Titan→
Related-party financings reshape Catheter Precision (NYSE: VTAK) structure
Catheter Precision (NYSE: VTAK) filed an amendment to its annual report, detailing extensive related-party transactions and director independence. These include an employment agreement with the CEO's daughter, financings with entities controlled by CEO David A. Jenkins involving preferred stock and warrants, and the formation of new subsidiaries. The amendment highlights a reshaped ownership and obligation structure, emphasizing the company's reliance on related-party financing.
APR 1·Stock Titan→
Catheter Precision (NYSE: VTAK) posts 2025 loss, revenue up 95% and buys Flyte aviation unit
Catheter Precision (NYSE: VTAK) reported a 95% revenue increase in 2025, reaching $819 thousand, but posted a GAAP net loss of $17.7 million. Despite the growth, the company highlights significant liquidity risks, stating it needs additional financing to fund operations through fiscal year 2026. VTAK has also strategically diversified by acquiring Flyte, a regional air mobility company, creating two distinct operating platforms in medical devices and aviation.
